INmune Bio Inc INMB

US Biotechnology

$1.75 ▼ -1.13% ($-0.02)

📅 Earnings This Week

Open $1.77

Prev Close $1.77

Day Range $1.72 – $1.79

52W Range $1.09 – $2.96

Market Cap $46.52M

Beta 0.90

EPS (TTM) $-1.69

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-02-04
Shares Out.	26,590,000
Website	inmunebio.com/ ↗
Phone	18589643720
Employees	21
Net Income	-$5.4M
Free Cash Flow	-$20.2M
Total Assets	$25.8M
Total Liabilities	$6.2M
Equity	$19.6M

About INmune Bio Inc

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

INmune Bio Inc is a publicly traded company under the ticker symbol INMB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.